NewsBenzingaNexentis Technologies' MitoCareX Bio Subsidiary Completes Initial Computational Screening Stage Under Its Drug-Discovery Initiative With Boltz Nexentis Technologies' MitoCareX Bio Subsidiary Completes Initial Computational Screening Stage Under Its Drug-Discovery Initiative With Boltz Benzinga 2026.10.26 12:18 (GMT+0) Open on Benzinga Other news IBM Stock Moves Lower: What's Going On? JP Morgan Maintains Overweight on Itau Unibanco Holding, Lowers Price Target to $9 Amazon’s Big Week: First a New James Bond, Then Anthropic’s IPO JP Morgan Maintains Overweight on Array Digital Infr, Lowers Price Target to $43 JP Morgan Maintains Overweight on Allstate, Lowers Price Target to $291 JP Morgan Maintains Overweight on Wise Group, Raises Price Target to $17.8